Clinical Guides
Sickle Cell Disease
A clinically focused clinical guide to diagnosing sickle cell disease, preventing organ injury, treating acute complications, and delivering equitable longitudinal care in India.
MedNext Academy | 15 min read
Sickle Cell Disease
A clinically focused clinical guide to diagnosing sickle cell disease, preventing organ injury, treating acute complications, and delivering equitable longitudinal care in India.
Summary
Sickle cell disease (SCD) is a group of inherited haemoglobin disorders in which haemoglobin S is present with another pathogenic beta-globin allele, most commonly HbSS but also HbS/beta-zero-thalassaemia, HbS/beta-plus-thalassaemia and selected compound heterozygous states. Deoxygenated HbS polymerises, making red cells rigid and adhesive. Recurrent vaso-occlusion, haemolysis, inflammation, endothelial injury and functional asplenia can affect nearly every organ. Sickle cell trait is a carrier state, not a mild form of SCD, and usually does not cause the chronic haemolysis or recurrent vaso-occlusive complications of disease.
Presentation varies with genotype, fetal haemoglobin, co-inherited modifiers, environment and access to preventive care. Infants may be asymptomatic until fetal haemoglobin falls, then present with dactylitis, severe infection, pallor or splenic sequestration. Across life, complications include acute pain, acute chest syndrome, stroke, severe infection, aplastic or haemolytic crises, priapism, avascular necrosis, kidney disease, retinopathy, pulmonary disease, leg ulcers, pregnancy complications and chronic pain. A person's usual haemoglobin, spleen size, oxygen saturation, pain plan and transfusion history are essential baselines.
Diagnosis uses a quality-assured haemoglobin-separation method, interpreted with CBC, reticulocyte count, age, iron status and transfusion history; molecular testing resolves uncertain or compound genotypes. Care combines vaccination and infection prevention, education, hydroxyurea or other appropriate disease-modifying treatment, organ surveillance, rapid protocol-driven acute care, selective simple or exchange transfusion, and assessment for haematopoietic cell transplantation. The National Sickle Cell Anaemia Elimination Mission creates an Indian screening and continuity framework, but a positive field screen requires confirmation and linkage, not public labelling. This educational draft is quarantined following MedNext Clinical Team review and cannot replace an individual emergency, analgesia, hydroxyurea, transfusion, pregnancy or transplant plan.
How Common Is It?
SCD is an important Indian public-health problem with a highly uneven distribution. The National Mission initially prioritises states and districts with higher prevalence, including many tribal and other historically underserved populations, while planning phased expansion. National targets describe people offered screening, not the number of confirmed disease cases. Estimates based on carrier frequency, selected community surveys or programme dashboards are not interchangeable with a population-based registry. Testing method, age, migration, genotype definition and confirmation rate all affect the number reported.
Prevalence is substantial in parts of central, western, eastern and southern India, but SCD also occurs outside conventionally labelled high-risk groups. Tribal identity is neither a diagnostic test nor a reason to stereotype. Conversely, clinicians in lower-prevalence cities can miss disease in migrants, mixed families or adults whose childhood records are unavailable. The Arab-Indian beta-globin haplotype is often associated with higher fetal haemoglobin and, on average, a different phenotype from some African cohorts; it does not guarantee mild disease. Severe acute chest syndrome, stroke, kidney disease, pregnancy complications and early mortality still occur.
Programme success requires separate denominators for screened, screen-positive, confirmatory-tested, trait, disease, genotype-defined, registered, linked to care and retained in care. A dashboard total cannot show whether a child received penicillin, vaccination, hydroxyurea monitoring or stroke-risk screening. Likewise, hospital admissions measure acute burden but miss people unable to reach care. For a patient, genotype and longitudinal phenotype matter more than a national estimate. For a district, reliable confirmatory laboratories, emergency protocols, hydroxyurea supply, transfusion support, counselling, referral transport and adult transition are more useful capacity measures than prevalence alone.
Risk Factors
SCD is inherited in an autosomal-recessive pattern. A child is at risk when both biological parents carry HbS or when one carries HbS and the other carries a clinically important beta-globin variant such as beta-thalassaemia, HbC, HbD Punjab or another interacting allele. Each pregnancy has its own probability based on the parental genotypes; previous healthy or affected children do not change the Mendelian probability for the next conception. Carrier screening should be voluntary and followed by confirmatory testing and non-directive counselling. Consanguinity can increase the chance that partners share an allele but must be discussed without blame or cultural judgement.
Triggers do not cause the genetic disorder, but can precipitate complications. Dehydration, infection, hypoxaemia, temperature extremes, intense unaccustomed exertion, fasting and physiological stress may contribute to vaso-occlusion in some people. Individual triggers are inconsistent, and attributing every episode to behaviour can delay evaluation of infection, acute chest syndrome, osteomyelitis or another emergency. Baseline disease severity is influenced by genotype, fetal haemoglobin, alpha-thalassaemia co-inheritance, prior splenic dysfunction, renal or cardiopulmonary disease, pregnancy and treatment access.
Treatment-related risks must be recorded. Transfusion can cause alloimmunisation, delayed haemolytic reaction, hyperhaemolysis and iron overload; these risks rise when antibody histories are fragmented or donor and recipient antigens differ. Hydroxyurea requires reliable laboratory follow-up and reproductive counselling. Splenectomy, central venous access, chronic opioid exposure and repeated hospitalisation introduce additional infection, thrombosis and psychosocial risks. Structural inequities—including long travel, medicine interruption, disbelief of self-reported pain, stigma around trait results and poor transition to adult care—are clinical risk multipliers. A risk assessment should therefore include organ history, prior crises, antibodies, adherence barriers, mental health and the patient's own acute-care plan rather than genotype alone.
Diagnosis
History
Ask about newborn or community screening, confirmatory reports, genotype, family history and parental results. Establish age at first dactylitis, pallor, jaundice, infection, pain or transfusion. Record the person's steady-state haemoglobin, reticulocyte count, oxygen saturation and spleen size; frequency, location and usual response of pain; acute chest syndrome, stroke or transient neurological symptoms; splenic sequestration; priapism; avascular necrosis; kidney, eye or gallbladder disease; leg ulcers; pregnancy outcomes; and school or work effects. Obtain a complete transfusion, antibody and reaction history. Recent transfusion and hydroxyurea alter haemoglobin fractions and indices.
Examination
First assess airway, breathing, circulation, mental state, temperature, pain and oxygenation. Compare with the individual's baseline rather than using population norms alone. Look for pallor, jaundice, dehydration, respiratory distress, focal chest signs, splenic enlargement, hepatomegaly, neurological deficit, bone or joint inflammation, leg ulcers and signs of heart failure. In a child, plot growth and teach caregivers how the usual spleen feels when appropriate. A normal examination between episodes does not mean absent organ injury, and pain intensity cannot be inferred from appearance or vital signs.
Investigations
Confirm disease with HPLC, capillary electrophoresis or another validated separation method that quantifies HbS, HbF, HbA2 and HbA where technically appropriate. Interpret age, transfusion timing and full blood count; HbA after transfusion does not exclude HbSS, while microcytosis may suggest iron deficiency or HbS/beta-thalassaemia. Molecular testing resolves ambiguous patterns and supports prenatal diagnosis. In an acute event, use CBC, reticulocytes, bilirubin, renal and liver tests, cultures, chest imaging, blood gas or other tests according to syndrome. A low reticulocyte response with acute anaemia suggests marrow suppression; a rapid haemoglobin fall with splenomegaly suggests sequestration. Neurological symptoms require emergency brain and vascular imaging without waiting for routine haemoglobin testing. Longitudinal care includes age- and genotype-appropriate kidney, eye, neurological, pulmonary and iron assessment under current specialist protocols.
Differential Diagnosis
Acute limb, back, rib or abdominal pain may be vaso-occlusive, but the differential remains broad. Osteomyelitis, septic arthritis, trauma, appendicitis, cholecystitis, renal colic, pancreatitis, pelvic pathology, avascular necrosis and thrombosis can coexist with SCD. Fever, focal swelling, persistent local tenderness, neurological change or an atypical course should prompt targeted investigation. Dactylitis in infancy is characteristic but cellulitis, trauma and other inflammatory causes should be considered. Chronic daily pain may include nociceptive, neuropathic, central sensitisation, musculoskeletal and psychosocial components rather than repeated identical acute crises.
Chest pain, fever, cough or hypoxaemia raises acute chest syndrome, which may reflect infection, infarction, atelectasis or fat embolism and can progress quickly. Pneumonia, asthma, pulmonary embolism, heart failure and pneumothorax are important alternatives or contributors. New weakness, speech disturbance, seizure, severe headache or altered behaviour may be overt stroke, haemorrhage, venous thrombosis, infection or metabolic disturbance. A normal early examination does not safely exclude evolving cerebral disease.
Acute anaemia may result from splenic or hepatic sequestration, parvovirus-associated aplasia, accelerated haemolysis, delayed haemolytic transfusion reaction, hyperhaemolysis, bleeding, malaria or other infection. Reticulocyte pattern, spleen size and transfusion timing distinguish mechanisms. Baseline microcytosis requires consideration of HbS/beta-thalassaemia, alpha-thalassaemia and iron deficiency; do not automatically prescribe iron. Trait must be distinguished from disease because HbAS does not explain recurrent haemolytic anaemia or classic vaso-occlusive illness under ordinary conditions. Other haemoglobin variants can co-elute on screening platforms. When symptoms, genotype and laboratory pattern disagree, repeat confirmatory testing through a reference laboratory and reassess for a second diagnosis.
Management
Every person with SCD needs a longitudinal plan spanning preventive care, disease modification, acute access and organ surveillance. Confirm immunisations, additional protection against encapsulated organisms under the Indian schedule and local policy, and age-appropriate antimicrobial prophylaxis. Teach fever, splenic enlargement, neurological symptoms, chest symptoms, priapism and dehydration safety-netting. Provide a written pain plan, baseline observations, genotype, transfusion requirements, antibodies and specialist contact. Hydroxyurea should be offered when indicated using a monitored protocol; adherence support and reliable supply are as important as the prescription. Nutrition, school, work, mental health, reproductive health and transition to adult services require active planning.
Acute vaso-occlusive pain needs prompt compassionate assessment, early analgesia based on prior effective therapy and repeated reassessment. Evaluate for a complication rather than making pain relief contingent on proof. Encourage oral fluids when safe; intravenous fluid is for a clinical deficit and excessive administration can worsen pulmonary complications. Use incentive spirometry for admitted patients with chest or upper abdominal pain where feasible. Fever requires rapid infection assessment and empiric antimicrobial treatment according to age, vaccination, local resistance and clinical severity. Acute chest syndrome requires oxygen when hypoxaemic, analgesia, respiratory support, infection treatment and early haematology/transfusion input; simple or exchange transfusion depends on severity and baseline.
Transfusion is selective, not routine for uncomplicated pain or chronic baseline anaemia. Indications include defined acute and preventive settings such as severe acute chest syndrome, acute stroke management, selected perioperative care and chronic stroke prevention. Match red-cell antigens and retrieve all historical antibodies. Disease-modifying and potentially curative options evolve: HSCT may benefit selected patients after shared risk discussion, while gene-based therapies remain specialised and access-limited. Chronic kidney, eye, bone, pulmonary, neurological and pain complications need multidisciplinary care. Pregnancy is high risk and requires preconception or early combined obstetric-haematology review. A foreign guideline informs principles but does not establish Indian drug approval, transfusion capacity or transplant eligibility.
Prescribing Information
Hydroxyurea is a specialist-managed disease-modifying medicine that increases fetal haemoglobin and reduces important complications in many patients. Before starting, confirm diagnosis, indication, blood counts, renal and hepatic function, pregnancy status where relevant, contraception and fertility counselling, and the ability to obtain monitoring. Dose initiation, escalation, toxicity thresholds and treatment interruptions must follow the current Indian product label and local protocol. Explain that laboratory changes can indicate biological effect but do not replace clinical review. Cytopenia, severe infection, pregnancy planning, renal impairment, non-adherence or an interrupted supply requires structured reassessment, not unsupervised dose adjustment.
Acute analgesia should use a patient-specific protocol with rapid administration and frequent reassessment. Base opioid decisions on pain severity, previous response, current sedation, respiratory risk, organ function and concurrent medicines. Avoid undertreatment driven by stigma and avoid unsafe escalation without monitoring. NSAIDs require renal, gastrointestinal and bleeding assessment and are not suitable for every patient. Paracetamol contributes to multimodal care but has dose limits. Chronic opioid therapy is not simply an extension of acute dosing; define functional goals, harms, monitoring and an exit strategy with pain expertise. Non-pharmacological measures can complement but must not delay effective analgesia.
Antibiotics for fever and acute chest syndrome follow local microbiology, age and illness severity. Transfusion must specify indication, component, antigen matching, target and monitoring; unnecessary transfusion can be harmful. L-glutamine, crizanlizumab, voxelotor and gene-based products have changing international regulatory status and uneven availability; some foreign approvals or recommendations may no longer be current. Confirm CDSCO status, label, evidence and institutional formulary before use. This guide gives no individual dose. Pregnancy and lactation require medicine-by-medicine review, and live vaccines, antimicrobial prophylaxis and post-splenectomy plans must be reconciled with the current Indian immunisation and specialist protocol.
When to Refer
Any positive field or solubility screen requires confirmatory haemoglobin analysis and linkage to a clinician who can distinguish trait from disease. Refer infants, children or adults with a disease pattern, unexplained haemolysis, abnormal fractions or a compound variant to a haemoglobinopathy service. A newborn or infant result should trigger prompt preventive-care review before symptoms appear. Genetic counselling is appropriate for carriers, affected people and reproductive partners, but must be confidential, comprehensible and non-directive. Molecular genetics is needed when separation results are ambiguous or prenatal testing is contemplated.
Known SCD needs regular specialist follow-up even when crises are infrequent. Escalate for recurrent admissions, increasing pain, acute chest syndrome, neurological events, renal decline, albuminuria, retinopathy, avascular necrosis, leg ulceration, priapism, pulmonary symptoms, pregnancy, growth or pubertal delay, alloantibodies, delayed transfusion reactions or rising iron burden. Refer early for HSCT discussion when disease severity, donor options and patient priorities make it relevant. Chronic pain benefits from a multidisciplinary service able to address nociceptive and neuropathic mechanisms, mental health, sleep and function without discrediting the patient's report.
Emergency transfer is required for suspected stroke, acute chest syndrome with deterioration, severe hypoxaemia, sepsis, splenic sequestration, profound symptomatic anaemia, priapism lasting four hours or more, major transfusion reaction, hyperhaemolysis, pregnancy emergencies or uncontrolled pain with diagnostic concern. Speak directly to the receiving service and send the baseline haemoglobin, genotype, antibody history, recent transfusions and treatments. In India, confirm whether exchange transfusion, paediatric intensive care, compatible blood or neuroimaging is available; transfer delay can be dangerous. District and primary teams remain essential after tertiary review, but a discharge summary must convert recommendations into locally feasible medicines, tests, emergency thresholds and follow-up contacts.
Red Flags
Fever in SCD can precede overwhelming bacterial infection because splenic function is impaired early in many genotypes. Treat it as urgent, particularly in children, people with a central line or those who appear unwell. New cough, chest pain, tachypnoea, falling oxygen saturation or a pulmonary infiltrate suggests acute chest syndrome; deterioration can be rapid and a seemingly small infiltrate does not imply low risk. Severe pallor, lethargy, tachycardia and an enlarging spleen indicate possible sequestration. A sudden anaemia with low reticulocytes suggests aplastic crisis.
Any focal weakness, facial asymmetry, speech or visual change, seizure, severe unusual headache, ataxia, confusion or altered behaviour requires an emergency stroke pathway and haematology involvement. Do not wait for symptoms to resolve or for a routine clinic. Priapism persisting four hours is a urological emergency; recurrent shorter episodes also require preventive review. Acute abdominal pain with guarding, persistent vomiting, jaundice or circulatory compromise should not be labelled a pain crisis without evaluating hepatobiliary, splenic, gastrointestinal and vascular causes.
After transfusion, fever, dyspnoea, hypotension, pain, haemoglobinuria or urticaria can be an acute reaction. Days to weeks later, haemoglobin falling below the pre-transfusion level, jaundice, dark urine or escalating pain can signal delayed haemolytic reaction or hyperhaemolysis; further transfusion without expert planning may worsen it. New breathlessness, oedema, severe hypertension, declining urine output or haematuria suggests organ injury. During analgesia, increasing sedation, hypoventilation or hypoxia requires immediate review. In pregnancy, pain, fever, hypoxia, hypertension, bleeding or reduced fetal movement warrants urgent combined assessment. Dismissal of pain or delayed analgesia is itself a safety failure and should trigger escalation through the acute-care protocol.
Indian Clinical Context
The National Sickle Cell Anaemia Elimination Mission aims to expand awareness, population screening, confirmatory diagnosis, counselling, registration and care, initially emphasising higher-prevalence areas. A screening card or portal result should travel with the person, but it must clearly distinguish provisional screen, trait and confirmed disease. Solubility tests cannot define genotype and may be unreliable in newborns, severe anaemia or after transfusion. Programmes should publish confirmation and linkage rates, not only screening totals. Consent, privacy and protection from discrimination in education, employment, insurance and marriage discussions are essential.
Care is distributed across Ayushman Arogya Mandirs, primary centres, district hospitals, medical colleges and centres of excellence, with wide variation in laboratory, hydroxyurea, transcranial Doppler, MRI, transfusion and intensive-care capacity. A practical shared-care plan should name who renews hydroxyurea, checks counts, supplies prophylaxis, responds to fever, manages acute pain and retrieves antibodies. Repeated travel and medicine stock-outs are not patient non-adherence; they are system defects to document and address. Blood services must preserve antibody histories across facilities and plan antigen-matched units before elective procedures.
ASH recommendations provide rigorous evidence on pain, transfusion and cerebrovascular care, but much evidence comes from HbSS or HbS/beta-zero cohorts in high-resource systems. Indian genotype distributions, fetal-haemoglobin levels, infection epidemiology, donor antigen patterns, analgesic availability and referral capacity differ. The 2016 NHM clinical guidance and 2023 Mission roadmap remain foundational, yet older medicine doses and statements must be checked against current national and institutional protocols. The Arab-Indian haplotype cannot justify reduced surveillance. Priorities for Indian evidence include genotype-specific natural history, adult and pregnancy outcomes, renal and neurological burden, pain inequity, implementation effectiveness and patient-reported outcomes. Community participation should shape services, not merely increase testing numbers.
NMC Competency Mapping
The NMC CBME curriculum expects an Indian medical graduate to understand haemolytic anaemia and haemoglobinopathies, recognise sickle cell complications and provide safe initial care and referral. Relevant pathology competencies cover haemolysis, haematological indices, peripheral blood findings and the pathogenesis and features of sickle cell anaemia and thalassaemia. Paediatrics competencies integrate aetiopathogenesis, clinical presentation and management principles for haemolytic anaemias, while clinical skills include history, pallor, jaundice, organomegaly and interpretation of basic investigations. Transfusion competencies address components, compatibility and reaction recognition. Exact 2024 wording and numbering should be verified before curriculum or logbook publication.
A learner should explain HbS polymerisation, vaso-occlusion, haemolysis and functional asplenia; distinguish trait from disease; interpret a CBC, reticulocyte count and basic haemoglobin-separation pattern in context; and recognise the effects of infancy and recent transfusion. They should elicit a crisis, organ, medicine and antibody history, assess pain without bias, compare observations with baseline, and identify fever, acute chest syndrome, stroke, sequestration, aplasia, priapism and transfusion reaction. Preventive-care knowledge includes vaccination, infection prophylaxis, hydroxyurea principles, organ surveillance, reproductive counselling and transition.
Competence is bounded. Undergraduate education does not authorise independent hydroxyurea titration, opioid protocol design, exchange-transfusion prescription, interpretation of rare variants, prenatal diagnosis or HSCT selection. Simulation should test first-hour actions: analgesia with reassessment, sepsis evaluation, oxygen for hypoxaemia, early imaging and specialist contact for neurological deficit, and safe transfusion history retrieval. Case assessment should include a screen-positive asymptomatic adolescent, an infant with an enlarging spleen, an adult with atypical chest pain and a recently transfused patient with worsening anaemia. Strong answers identify uncertainty, protect confidentiality and build a workable referral rather than reproduce a memorised dose table.
Key Exam Pearls for NEET PG
SCD is caused by inheritance of HbS with another pathogenic beta-globin allele; HbSS is sickle cell anaemia, while HbS/beta-thalassaemia is a compound state. A valine replaces glutamic acid at position six of the beta chain. Deoxygenation promotes HbS polymerisation, sickling, haemolysis and vaso-occlusion. Fetal haemoglobin inhibits polymerisation, explaining relative protection in early infancy and part of hydroxyurea's benefit. Trait is usually HbAS and is not chronic SCD. Dactylitis may be the first painful manifestation in infancy; functional asplenia increases risk from encapsulated bacteria.
Pain is diagnosed clinically but alternative emergencies must remain active. Acute chest syndrome combines a new pulmonary infiltrate with compatible respiratory or systemic features and may follow pain, infection or surgery. Splenic sequestration causes rapid splenic enlargement and acute anaemia with reticulocytosis; aplastic crisis commonly causes reticulocytopenia. Stroke may be overt or silent, and transcranial Doppler identifies elevated risk in selected children with severe genotypes under protocol. Priapism lasting four hours is an emergency. Gallstones reflect chronic haemolysis; avascular necrosis, kidney disease and retinopathy are chronic complications.
Hydroxyurea raises HbF and reduces major clinical events but requires count and organ-function monitoring. Do not transfuse uncomplicated pain or steady-state anaemia routinely. Simple and exchange transfusion have different goals; antigen matching reduces alloimmunisation, and delayed haemolytic reaction may occur after antibodies become undetectable. In acute stroke or severe acute chest syndrome, early specialist transfusion planning is critical. Fever requires urgent assessment and antibiotics after appropriate cultures when feasible, without harmful delay. Diagnosis rests on haemoglobin separation and genotype context, not a solubility screen alone. In India, Mission screening must lead to confirmation, counselling and sustained care rather than trait stigma or an isolated card.
Frequently Asked Questions
Is sickle cell trait the same as a mild form of sickle cell disease?
No. Trait usually means one HbS allele with one usual beta-globin allele and does not cause the chronic haemolysis and recurrent vaso-occlusive complications of SCD. The distinction requires a confirmatory haemoglobin pattern interpreted with age and transfusion history; a screening test alone should not label either state.
Should every painful episode in sickle cell disease be treated as a routine crisis?
No. Analgesia should be prompt, but clinicians must also look for acute chest syndrome, infection, osteomyelitis, septic arthritis, abdominal disease, thrombosis, avascular necrosis and other causes, especially when symptoms are focal, febrile, neurologic, respiratory or different from the person's usual pattern.
Why must old red-cell antibodies be recorded even if the current screen is negative?
Some antibodies fall below laboratory detection but can reappear after exposure and cause delayed haemolytic transfusion reactions. A lifelong, portable antibody and reaction record allows the blood bank to avoid implicated antigens and plan compatible units before an emergency or elective procedure.
What does a positive community sickle screening result mean?
It means confirmatory testing and counselling are needed. Field tests may detect HbS but usually cannot establish the full genotype or reliably separate trait from every disease state. The result should remain confidential, be confirmed by a quality-assured laboratory and lead to appropriate preventive care or reproductive counselling.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic